Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Our innovation /
      3. Focus areas/
      4. Oncology/
      5. Oncology newsroom /
      6. ASCO/EHA 2023
      ASCO/EHA 2023
      Welcome to the Janssen Oncology Virtual Newsroom.
      lebowitz_qc_v3.jpg
      Peter Lebowitz, M.D., Ph.D.
      Global Therapeutic Area Head Oncology
      Janssen Research & Development, LLC
      brewer_qc_v2.jpg
      Tyrone Brewer
      U.S. President, Oncology
      Janssen Biotech, Inc
      Latest news
      Oncology
      Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
      May 18, 2023
      United States
      Read more
      Abstract chart and data research
      Oncology
      Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
      June 5, 2023
      United States
      Read more
      Oncology
      CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
      June 5, 2023
      United States
      Read more
      Oncology
      Janssen Announces BALVERSA® (erdafitinib) Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment
      June 5, 2023
      United States
      Read more
      Oncology
      New Long-Term Data from the CHRYSALIS Study Show Median PFS Not Reached after 33.6 Months of Follow Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced NSCLC
      June 4, 2023
      United States
      Oncology
      Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
      June 3, 2023
      United States
      Read more
      Oncology
      Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
      June 3, 2023
      United States
      Read more
      Featured stories
      precision_onc.png
      Perspective: Delivering precision medicine for bladder cancer through collaboration
      Read more
      nature.png
      How to get in front of prostate cancer
      Read more
      biopharma_dive_podcast.png
      Breaking down barriers: how bladder cancer innovations benefit patients and treatments for other diseases
      Read more
      targeted_onc.png
      Biomarker testing in non-small cell lung cancer.
      Read more
      nature_2.png
      An integrated approach combining prevention, interception and treatment to tackle lung cancer
      Read more
      stat.png
      In relentless pursuit of curing multiple myeloma
      Read more
      jnj.png
      Johnson & Johnson Oncology
      Read more
      biopharma_dive_2_v2.png
      Changing the trajectory of blood cancers with transformational and potentially curative therapies at ASH
      Read more